Silence Therapeutics, an RNA interference (RNAi) therapeutics company, has promoted Tony Sedgwick to chief executive from chief business officer.
The firm, which has operations in Berlin, Germany and London, UK has also announced the resignation of director Thomas Christely for personal reasons.
Sedgwick joined Silence in September 2011 to lead a new business development team and has been instrumental since then in helping shape the company's future strategy. He has extensive experience from European life science companies including more than 15 years at Roche. Prior to joining Silence, he was ceo of Novacta and chairman of Norwegian biotech Plastid.